CN110687301A - Reagent card for quantitatively detecting tumor necrosis factor alpha and preparation method thereof - Google Patents
Reagent card for quantitatively detecting tumor necrosis factor alpha and preparation method thereof Download PDFInfo
- Publication number
- CN110687301A CN110687301A CN201911032652.2A CN201911032652A CN110687301A CN 110687301 A CN110687301 A CN 110687301A CN 201911032652 A CN201911032652 A CN 201911032652A CN 110687301 A CN110687301 A CN 110687301A
- Authority
- CN
- China
- Prior art keywords
- solution
- necrosis factor
- tumor necrosis
- nitrocellulose membrane
- immunofluorescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 49
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title claims abstract description 49
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 68
- 239000012528 membrane Substances 0.000 claims abstract description 56
- 102100040247 Tumor necrosis factor Human genes 0.000 claims abstract description 51
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 44
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 44
- 238000001514 detection method Methods 0.000 claims abstract description 41
- 238000010166 immunofluorescence Methods 0.000 claims abstract description 38
- 238000003908 quality control method Methods 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000002250 absorbent Substances 0.000 claims abstract description 9
- 230000002745 absorbent Effects 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 98
- 239000007853 buffer solution Substances 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 15
- 241000283707 Capra Species 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000002372 labelling Methods 0.000 claims description 10
- 238000007865 diluting Methods 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000009210 therapy by ultrasound Methods 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000003317 immunochromatography Methods 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 206010054094 Tumour necrosis Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical group 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- -1 rare earth lanthanide Chemical class 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007076 release of cytoplasmic sequestered NF-kappaB Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a reagent card for quantitatively detecting tumor necrosis factor alpha, which comprises a box body and a reagent strip arranged in the box body, wherein the reagent strip comprises a lining, an immune nitrocellulose membrane is arranged on the lining, one end of the immune nitrocellulose membrane is linked with an immunofluorescence material release pad, and the other end of the immune nitrocellulose membrane is linked with absorbent paper; the immunofluorescence material release pad is coated with a TNF alpha monoclonal antibody; the immune nitrocellulose membrane is provided with a TNF alpha detection line and a quality control line, and the TNF alpha detection line is positioned between the quality control line and the immunofluorescence material release pad; the box body is provided with a sample adding hole and an observation window. The invention also discloses a preparation method of the kit for quantitatively detecting the tumor necrosis factor alpha. The invention adopts dry-type fluorescence immunochromatography and double-antibody sandwich method to detect the concentration of the tumor necrosis factor alpha in the sample, can effectively eliminate the interference of nonspecific fluorescence, improves the analysis sensitivity and the accuracy of quantitative determination, and is suitable for the technical field of the detection of the tumor necrosis factor alpha.
Description
Technical Field
The invention belongs to the technical field of biology, and relates to a reagent card, in particular to a reagent card for quantitatively detecting tumor necrosis factor alpha and a preparation method thereof.
Background
Tumor necrosis factor is a cytokine with a wide range of biological activities. Shalalby named tumor necrosis factor alpha from macrophage in 1985, and research shows that the tumor necrosis factor alpha is closely related to apoptosis, and some cell surfaces have death receptors which sense cell cycle environment death signals and stimulate the apoptosis mechanism in cells through the binding of ligand and receptor. Tumor necrosis factor is a 17kDa nonglycosylated protein whose biologically active composition is in the form of a trimer. In addition to the soluble component alpha TNF, a membrane-bound component with a molecular weight of 17kDa is present on the surface of the TNF-producing cells, which acts as a tumor necrosis factor sink and is proteolytically separated from the cell surface.
The human TNF-. alpha.precursor consists of 233 amino acids (26 kDa) and contains a signal peptide consisting of 76 amino acid residues, which is cleaved off by the TNF converting enzyme TACE to form the mature 157 amino acid residues TNF-. alpha. (17 kDa). Since there is no methionine residue, there is no glycosylation site, with the two cysteines at positions 69 and 101 forming an intramolecular disulfide bond. Human TNF-alpha has 79 percent of amino acid composition homology with mouse TNF-alpha, and the biological effect of TNF-alpha has no obvious species specificity. Recently, it has been reported that 155 amino acid human TNF-alpha with less 2 amino acids (Val, Arg) at the N-terminal is expressed by genetic engineering technology, and has better biological activity and anti-tumor effect. In addition, 7 amino acid residues at the amino terminal of the TNF-alpha molecule are deleted by a genetic engineering method, 8Pro, 9Ser and 10Asp are changed into 8Arg, 9Lys and 10Arg, or 157Leu is changed into 157Phe at the same time, the activity of the modified TNF-alpha for killing L929 cells in vitro is increased by about 1000 times compared with the natural TNF, and the in vivo tumor hemorrhagic necrosis effect is also obviously increased. The natural form in which TNF- α and β exert their biological effects is a homotrimer.
Alpha tumor necrosis factor can be produced by a variety of cells, for example macrophages, CD4+ T cells and natural killer cells can produce alpha tumor necrosis factor following lipopolysaccharide stimulation. In addition, smooth muscle cells, segmented nucleus neutrophils, astrocytes and a large number of tumor cells can produce alpha tumor necrosis factor. The action of alpha tumor necrosis factor is produced by two distinct receptors on the cell surface, which are called alpha tumor necrosis factor receptor i (p55) and alpha tumor necrosis factor receptor ii (p75), respectively. These receptors are recognized on the surface of almost all cell types, except red blood cells. In addition to the cell binding component, the lytic component of the alpha tumor necrosis factor receptor is generally believed to have the ability to bind alpha tumor necrosis factor.
TNF alpha participates in the generation and development process of various immune inflammations and is a main medium of autoimmune diseases, systemic inflammatory response syndrome and the like; mainly produced by mononuclear macrophages, neutrophils, NK cells, activated T lymphocytes and the like; the biological activities of TNF α are very complex, including the regulation of hematopoiesis, immunity and inflammation, the effects on blood vessels and coagulation and on various organs (liver, heart, bone, cartilage, muscle and other tissues), the ability to enhance the effects of cytotoxic T cells, increase the expression of MHC antigens, causing leukocytosis and enhanced endothelial cell adsorption; in addition, it can inhibit various tumor cells and virus-infected cells. Normally, low levels of TNF α are present in plasma and have the effect of enhancing antiviral, antitumor, and anti-infective properties. TNF α plays an important role in inflammatory response, development of immune system, apoptosis and lipid metabolism, and is closely related to many diseases including asthma, crohn's disease, rheumatoid arthritis, neuropathic pain, obesity, diabetes, autoimmune diseases and tumors. However, since abnormality of TNF α has no disease specificity, detection of TNF α concentration in serum or body fluid cannot be a specific index for differential diagnosis of diseases, but can be an evaluation index for disease state change, therapeutic effect, and prognosis.
The tumor necrosis factor alpha is an important proinflammatory cytokine, the level of the tumor necrosis factor alpha is obviously increased within 24 hours in cerebrospinal fluid and serum of an acute stroke patient, a large amount of the tumor necrosis factor alpha can aggravate brain tissue damage and is positively correlated with the severity of the disease, and the tumor necrosis factor alpha plays an important role in inflammation caused by early stroke. Transient cerebral ischemia mouse model shows that tumor necrosis factor alpha can cause blood brain barrier permeability increase, and the anti-tumor necrosis factor antibody can obviously reduce blood brain barrier damage. Tumor necrosis factor alpha has an effect of damaging ischemic tissues and can induce damage to transplanted stem cells. The tumor necrosis factor alpha can also promote the continuous activation of NF-kappa B and induce apoptosis.
TNF alpha is one of important biological indexes of immunological research, and relates to occurrence mechanism, prognosis judgment and clinical treatment of various diseases such as infectious diseases, autoimmune diseases, tumors and the like, so that a simple and easy quantitative method is established, and accurate determination of TNF alpha levels in different samples has important significance for clinical research.
The POCT reagent has the advantages of simple operation, quick interpretation, low cost and the like, and is widely applied to the quick detection of diseases such as reproductive diseases, cardiovascular and cerebrovascular diseases, blood diseases, infection diseases, endocrine diseases and the like. Immunochromatography has been unable to perform accurate quantitative determination due to many interfering factors. The fluorescence immunochromatography method is characterized in that the antigen or the antibody is labeled by using a material, so that the interference of nonspecific fluorescence can be effectively eliminated, the analysis sensitivity is greatly improved, the accuracy of quantitative determination is improved, the detection method is convenient and easy to implement, the detection sensitivity and accuracy are high, the specificity is strong, a large number of samples can be simultaneously and rapidly detected, the time consumption of the method is low, and the precious time is saved for clinical patients.
If the fluorescence immunochromatography method can be adopted to detect the tumor necrosis factor alpha, the fluorescence immunochromatography method plays an important role in TNF-alpha related basic and clinical research.
Disclosure of Invention
The invention aims to provide a reagent card for quantitatively detecting tumor necrosis factor alpha, which adopts the fluorescence immunochromatography technology and the double-antibody sandwich method principle to measure the content of TNF alpha in human serum, plasma and whole blood samples.
The invention also aims to provide a preparation method of the reagent card for quantitatively detecting the tumor necrosis factor alpha.
In order to achieve the purpose, the invention adopts the following technical scheme:
a reagent kit card for quantitatively detecting tumor necrosis factor alpha comprises a lining, wherein an immune nitrocellulose membrane is arranged on the lining, one end of the immune nitrocellulose membrane is connected with an immunofluorescence material release pad, and the other end of the immune nitrocellulose membrane is connected with absorbent paper;
the immunofluorescence material release pad is coated with a fluorescently-labeled TNF alpha monoclonal antibody;
the immune nitrocellulose membrane is provided with a TNF alpha detection line coated with a TNF alpha monoclonal antibody and a quality control line coated with a goat anti-mouse IgG polyclonal antibody, and the TNF alpha detection line is positioned between the quality control line and the immunofluorescence material release pad;
and a sample adding hole is formed in the box body corresponding to the immunofluorescence material release pad, and an observation window is formed in the box body corresponding to the TNF alpha detection line and the quality control line.
As a limitation: the anti-TNF monoclonal antibody is a murine or rabbit antibody;
the polyclonal antibody is rabbit-derived, mouse-derived, chicken-derived and horse-derived.
As a second limitation: the TNF alpha monoclonal antibody coated by the immunofluorescence material release pad is marked by Eu fluorescent microspheres.
The preparation method of the reagent card for quantitatively detecting the tumor necrosis factor alpha comprises the following steps of sequentially carrying out,
firstly, preparing the immunofluorescence material release pad
Labeling an anti-TNF alpha monoclonal antibody-1 with a fluorescent material, preparing an anti-TNF alpha monoclonal antibody-1 solution labeled with an immunofluorescence material, adjusting the solution to a specified concentration range, spraying the solution on a release pad, and drying;
secondly, preparing the immune nitrocellulose membrane
Preparing a TNF alpha detection line by scribing an anti-TNF alpha monoclonal antibody-2 solution on a nitrocellulose membrane, preparing a quality control line by scribing a goat anti-mouse IgG solution on the nitrocellulose membrane, and drying;
third, sticking film
Sequentially sticking an immunofluorescence material release pad, an immunonitrocellulose membrane and absorbent paper on a lining to form a reagent strip;
fourthly, packaging
And (3) packing the dried reagent strip into a prepared box body to obtain the reagent card for quantitatively detecting the tumor necrosis factor alpha.
As a limitation: and after the fourth step is finished, the reagent card and the drying agent are filled into an aluminum foil bag, sealed and packaged.
As a second limitation: the first step is carried out according to the following step sequence,
firstly), adding a marking buffer solution into a fluorescent material, and diluting the fluorescent material to 0.2-0.3% to obtain a solution A;
wherein the amount of fluorescent material = batch volume × target fluorescent material concentration 0.25% ÷ original fluorescent material concentration 1%, the amount of added labeling buffer = batch volume-fluorescent material volume;
secondly), centrifuging the solution A for 10-20 minutes under the conditions of 12000-13000rpm, discarding the supernatant, redissolving the precipitate by using a marking buffer solution, performing ultrasonic treatment, centrifuging for 10-20 minutes under the conditions of 12000-13000rpm, discarding the supernatant, adding the marking buffer solution, and performing ultrasonic treatment to obtain a solution B;
thirdly) adding the EDC solution with the concentration of 0.01-0.03mL/mL and the NHS solution with the concentration of 0.08-0.2mL/mL into the solution B, and uniformly mixing for 0.5-1.5 hours to obtain a solution C;
wherein, the dosage of EDC solution = batch volume (0.01-0.03) mL/mL, and the dosage of NHS solution = batch volume (0.08-0.2) mL/mL;
centrifuging the solution C for 10-20 minutes under the conditions of 12000-13000rpm, discarding the supernatant, redissolving the precipitate by using a marking buffer solution, and performing ultrasonic treatment to obtain a solution D;
adding the antibody into the solution D, and stirring for 2-4 hours to obtain a solution E;
wherein the antibody dosage = batch volume × target antibody concentration 0.1-0.3mg/mL ÷ antibody concentration
Centrifuging the solution E for 10-20 minutes under the conditions of 12000-13000rpm, removing the supernatant, adding the TBS solution with batch volume into the precipitate, ultrasonically mixing the solution uniformly, and stirring the solution for 3-5 hours to obtain a solution F;
centrifuging the solution F for 10-20 minutes under the conditions of 12000-13000rpm, re-dissolving the precipitated immune material into a batch volume by using TBS, and performing ultrasonic treatment at 160-220W to obtain an immunofluorescence material diluted solution;
fourthly) spraying the immunofluorescence material diluted solution to a release pad according to the parameter of 2.0-3.0 mu L/cm, and then drying for 4-24 hours at the temperature of 40-45 ℃ to obtain the immunofluorescence material release pad;
batch volume refers to the volume of the immunofluorescent material dilution solution.
As a further limitation: the second step is carried out according to the following step sequence,
① quality control line solution preparation
Measuring a goat anti-mouse IgG solution, diluting the goat anti-mouse IgG solution with a CT-S buffer solution until the final concentration is 0.8-1.5mg/mL, and storing the diluted goat anti-mouse IgG solution at the temperature of 2-8 ℃ for later use;
② TNF alpha detection line solution preparation
Measuring an anti-TNF alpha monoclonal antibody-2, diluting the anti-TNF alpha monoclonal antibody-2 by using a CT-S buffer solution until the final concentration is 0.8-1.5mg/mL, and storing the anti-TNF alpha monoclonal antibody-2 at the temperature of 2-8 ℃ for later use;
③ spraying the prepared quality control line solution onto the nitrocellulose membrane according to the parameters of 2.0-3.0 muL/cm to prepare a quality control line, spraying the prepared TNF alpha detection line solution parameters onto the nitrocellulose membrane to prepare a TNF alpha detection line, and drying the nitrocellulose membrane at 40-45 ℃ for 4-24 hours to obtain the immune nitrocellulose membrane.
As a further limitation: the third step is carried out according to the following step sequence,
i, sticking the immune nitrocellulose membrane at the middle position of the gasket;
and II, attaching the water absorption paper to the water absorption paper end of the lining, covering the upper end of the attached immune nitrocellulose membrane downwards, covering the immune nitrocellulose membrane by 1.5-2 mm, and pressing.
III, attaching the immunofluorescence material release pad to the lower end of the immunonitrocellulose membrane, covering the immunonitrocellulose membrane by 1.5-2 mm, and pressing.
Due to the adoption of the technical scheme, compared with the prior art, the invention has the technical progress that:
(1) the reagent card provided by the invention has the advantages that the detection method is convenient and easy to implement when in use, the detection sensitivity and accuracy are high, the specificity is strong, the recovery rate is between 85% and 115% in the linear range of concentration, and the linearity is as follows: within a linear range of (10-1000) pg/mL, the correlation coefficient r is more than or equal to 0.990, and meanwhile, a large number of samples can be detected rapidly, so that the time consumption is low, and precious time is saved for clinical patients;
(2) the blank limit of the reagent card provided by the invention is not higher than 5 pg/mL;
(3) the reagent card provided by the invention has the following repeatability: in the linear interval of the reagent card, low-concentration and high-concentration TNF alpha samples are repeatedly detected for 10 times respectively, and the coefficient of variation CV is less than or equal to 15 percent;
(4) the material used for preparing the fluorescent material is a mixture of substances containing any one or more of europium (Eu), samarium (Sm), erbium (Er) and neodymium (Nd) in rare earth lanthanide elements; the lanthanide ion chelate has a long fluorescence decay time which is 106 times that of the conventional fluorescence, such as: when the fluorescence is measured by a fluorescence analyzer, after the excitation of the pulse light source, the measurement can be carried out after a certain time delay, at the moment, the short half-life fluorescence of other components is already decayed, and only Eu exists3+Specific fluorescence of the marker, by measuring Eu on test strip after immunoreaction3+The content of the chelate can be quantitatively obtained by referring to a standard concentration curve to obtain the concentration of the corresponding antigen in the sample to be detected;
(5) the reagent card provided by the invention has high detection speed, only needs 10 minutes in the whole process, and can realize the detection of a single sample or a large number of samples; the sensitivity is high, and the lowest detection unit is pg/mL; strong specificity and no cross interference with other markers of inflammation or immune diseases; the operation is simple and convenient, the operator can finish the operation according to the instruction without professional training, and the popularization and the use are easy; the detection sample range is wide, whole blood, serum and/or plasma can be used as test samples, the required reagent and sample amount are small, and the sample amount can be as low as 50-100 mu L.
The invention is applicable to the technical field of detection of tumor necrosis factor alpha.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention.
In the drawings:
FIG. 1 is a schematic structural view of example 1 of the present invention;
FIG. 2 is a partial structural view of a reagent strip according to embodiment 1 of the present invention.
In the figure: 1. a box body; 2. an observation window; 3. a reagent strip; 31. a lining; 32. an immunonitrocellulose membrane; 33. an immunofluorescent material release pad; 34. absorbent paper; 4. a quality control line; 5. a TNF alpha detection line; 6. and (4) sample adding holes.
Detailed Description
Preferred embodiments of the present invention will be described below with reference to the accompanying drawings. It should be understood that the preferred embodiments described herein are for purposes of illustration and explanation only and are not intended to limit the present invention.
Example 1A reagent card for quantitatively detecting TNF alpha
As shown in fig. 1 and 2, the present embodiment includes a cartridge 1 and a reagent strip 3 disposed in the cartridge 1. The reagent strip 3 comprises a lining 31, wherein an immune nitrocellulose membrane 32 is arranged on the lining 31, one end of the immune nitrocellulose membrane 32 is connected with an immunofluorescence material release pad 33, and the other end is connected with absorbent paper 34.
The immunofluorescent material release pad 33 is coated with a fluorescently labeled TNF α monoclonal antibody. A TNF alpha detection line 5 coated with a TNF alpha monoclonal antibody and a quality control line 4 coated with a goat anti-mouse IgG polyclonal antibody are arranged on the immune nitrocellulose membrane 32 in parallel, and the TNF alpha detection line 5 is positioned between the quality control line 4 and the immunofluorescence material release pad 33;
a sample adding hole 6 is arranged on the box body 1 corresponding to the position of the immunofluorescence material release pad 33, and an observation window 2 is arranged on the box body corresponding to the positions of the TNF alpha detection line 5 and the quality control line 4.
The anti-TNF monoclonal antibody is a murine or rabbit antibody, the polyclonal antibody is a rabbit, murine, chicken or horse antibody, and the TNF alpha monoclonal antibody coated by the immunofluorescence material release pad 33 is marked by Eu fluorescent microspheres.
In this embodiment, the case 1 and the lining 31 are made of plastic.
The working principle of the embodiment is as follows: in the embodiment, the concentration of the tumor necrosis factor alpha in the sample is detected by adopting a dry-type fluorescence immunochromatography technology and a double-antibody sandwich method principle; during detection, a blood sample is added into a sample adding hole 6 of the detection card, the tumor necrosis factor alpha in the sample and the fluorescence labeled anti-tumor necrosis factor alpha monoclonal antibody carry out immunoreaction to form an immunoconjugate, the conjugate is captured by the anti-tumor necrosis factor alpha monoclonal antibody of the TNF alpha detection line 5 when being chromatographed to the detection card TNF alpha detection line 5, and the fluorescence signal intensity at the TNF alpha detection line 5 is positively correlated with the concentration of the tumor necrosis factor alpha in the sample, so that the concentration of the tumor necrosis factor alpha in the sample can be detected by using an applicable dry fluorescence instrument. The direction of the arrow in FIG. 2 represents the direction of chromatography in actual use.
Example 2 preparation method of reagent card for quantitatively detecting tumor necrosis factor alpha
This example was used to prepare example 1, comprising the following steps carried out in sequence:
firstly, preparing an immunofluorescence material release pad 33
One) adding a labeling buffer solution into the fluorescent material, and diluting the fluorescent material to VOL1= 0.25%, obtaining a solution a;
wherein the amount of fluorescent material = batch volume × target fluorescent material concentration 0.25% ÷ original fluorescent material concentration 1%, the amount of added labeling buffer = batch volume-fluorescent material volume;
two) adding the solution A to n1Centrifuge t under the condition of 12500rpm1=15 min, the supernatant was discarded, the pellet was reconstituted with labeling buffer, sonicated, and then incubated at n2Centrifuge t under the condition of 12500rpm2=15 min, discarding the supernatant, adding a labeling buffer solution, and performing ultrasound to obtain a solution B;
three) concentration of VOL2EDC solution and concentration of =0.02mL/mLIs VOL3Adding the NHS solution with the concentration of =0.1mL/mL into the solution B, and uniformly mixing the solution B and the NHS solution3=1 hour, obtaining a solution C;
wherein, the dosage of the EDC solution = batch volume × 0.02mL/mL, and the dosage of the NHS solution = batch volume × 0.1 mL/mL;
adding solution C to n3Centrifuge t under the condition of 12500rpm4=15 min, discarding the supernatant, redissolving the precipitate with a labeling buffer solution, and performing ultrasound to obtain a solution D;
adding the antibody to the solution D, and stirring at room temperature5=3 hours, obtain solution E;
wherein antibody dosage = batch volume × target antibody concentration 0.25mg/mL ÷ antibody concentration
Adding solution E to n4Centrifuge t under the condition of 12500rpm6=15 min, discard supernatant, precipitate add batch volume TBS solution, mix by ultrasound, stir at room temperature t7=4 hours, obtaining a solution F;
adding solution F to n5Centrifuge t under the condition of 12500rpm8=15 min, redissolving the precipitated immune material with TBS solution to batch volume, obtaining an immunofluorescence material diluted solution after sonication with P = 200W;
fourthly) filling the immunofluorescence material diluted solution into a suitable container, connecting a pipeline, operating a driving system of an instrument, and setting the parameter of a spraying quantity system to be y1Adjusting the position of a spray head, operating an instrument, uniformly spraying the prepared immunofluorescence material diluted solution to a release pad, and drying in a drying oven at the temperature T of the drying oven1=42 ℃, drying time t9After the reaction lasts for 6 hours, the immunofluorescence material release pad 33 is obtained;
II, preparing an immune nitrocellulose membrane 32
The present step is carried out in the following order of steps,
① quality control line solution preparation
Measuring goat anti-mouse IgG solution, and diluting with CT-S buffer solution to final concentration
=1.1mg/mL in T2Storing at 2 deg.C for use;
② TNF alpha detection line solution preparation
Measuring anti-TNF alpha monoclonal antibody-2, and diluting with CT-S buffer solution to final concentration
=1.1mg/mL in T3Storing at 2 deg.C for use;
③ fixing the nitrocellulose membrane on the platform of a membrane spotting machine, loading the prepared quality control line solution and TNF alpha detection line solution into an applicable container, connecting pipelines, starting the membrane spotting machine driving system, setting system parameters, and setting the spraying amount system parameters as y2Adjusting the position of a spray head, operating the instrument, continuously spraying a nitrocellulose membrane to prepare a quality control line 4 and a TNF alpha detection line 5, and drying the nitrocellulose membrane in a drying oven at the temperature of T3=42 ℃ and drying time t10=6 hours, obtaining the immune nitrocellulose membrane 32;
third, sticking film
The present step is carried out in the following order of steps,
i, uncovering a paper sheet at the middle part of the gasket 31, pasting the immune nitrocellulose membrane 32 at the middle position of the gasket 31, twisting the gasket 31 back and forth to enable the adhesion to be firm, and strictly prohibiting pressing the nitrocellulose membrane by hands;
II, attaching the absorbent paper 34 to the absorbent paper end of the lining 31, covering the upper end of the attached immune nitrocellulose membrane 32 downwards, covering 1.5-2 mm of the immune nitrocellulose membrane 32, and pressing;
III, tearing off the paper sheet on the other side of the gasket 31, attaching an immunofluorescence material release pad 33 to the lower end of the immunonitrocellulose membrane 32, covering 1.5-2 mm of the immunonitrocellulose membrane 32, and pressing to obtain a card;
fourthly, cutting
Cutting the card into reagent strips 3 with consistent width;
five, package
And (3) putting the dried reagent strips 3 into the prepared box body 1, and then putting the reagent cards and the drying agents into an aluminum foil bag, sealing and packaging.
In this example, the batch volume refers to the volume of the immunofluorescence material diluted solution, and the labeling buffer is a Tris-HCl buffer of pH 8.010 mmol/L containing 2% BSA, 0.1% PEG4000, 5% trehalose, and 5% sucrose; TBS solution is 0.01M Tris buffer pH 8.0 + -0.05 containing 0.1% Tween-20 and 0.05% sodium azide; the CT-S buffer solution is 0.01-0.05M PBS buffer solution with pH7.4 and containing 3-4% of trehalose.
Example 3-6A method for preparing a reagent card for quantitatively detecting TNF-. alpha.
Examples 3-6 were prepared substantially identically to example 2, except for the differences in the parameters, as shown in table 1 below:
TABLE 1 parameters for examples 3-6
Claims (8)
1. The utility model provides a quantitative determination tumor necrosis factor alpha's reagent card, includes the box body and sets up the reagent strip in the box body, its characterized in that: the reagent strip comprises a lining, wherein an immune nitrocellulose membrane is arranged on the lining, one end of the immune nitrocellulose membrane is connected with an immunofluorescence material release pad, and the other end of the immune nitrocellulose membrane is connected with absorbent paper;
the immunofluorescence material release pad is coated with a fluorescently-labeled TNF alpha monoclonal antibody;
the immune nitrocellulose membrane is provided with a TNF alpha detection line coated with a TNF alpha monoclonal antibody and a quality control line coated with a goat anti-mouse IgG polyclonal antibody, and the TNF alpha detection line is positioned between the quality control line and the immunofluorescence material release pad;
and a sample adding hole is formed in the box body corresponding to the immunofluorescence material release pad, and an observation window is formed in the box body corresponding to the TNF alpha detection line and the quality control line.
2. The reagent card for quantitatively detecting tumor necrosis factor alpha according to claim 1, wherein: the anti-TNF monoclonal antibody is a murine or rabbit antibody;
the polyclonal antibody is rabbit-derived, mouse-derived, chicken-derived and horse-derived.
3. The reagent card for quantitatively detecting tumor necrosis factor alpha according to claim 1 or 2, wherein: the TNF alpha monoclonal antibody coated by the immunofluorescence material release pad is marked by Eu fluorescent microspheres.
4. A method for preparing the reagent card for quantitatively detecting tumor necrosis factor alpha according to any one of claims 1 to 3, wherein the method comprises the following steps: comprises the following steps which are carried out in sequence,
firstly, preparing the immunofluorescence material release pad
Labeling an anti-TNF alpha monoclonal antibody-1 with a fluorescent material, preparing an anti-TNF alpha monoclonal antibody-1 solution labeled with an immunofluorescence material, adjusting the solution to a specified concentration range, spraying the solution on a release pad, and drying;
secondly, preparing the immune nitrocellulose membrane
Preparing a TNF alpha detection line by scribing an anti-TNF alpha monoclonal antibody-2 solution on a nitrocellulose membrane, preparing a quality control line by scribing a goat anti-mouse IgG solution on the nitrocellulose membrane, and drying;
third, sticking film
Sequentially sticking an immunofluorescence material release pad, an immunonitrocellulose membrane and absorbent paper on a lining to form a reagent strip;
fourthly, packaging
And (3) packing the dried reagent strip into a prepared box body to obtain the reagent card for quantitatively detecting the tumor necrosis factor alpha.
5. The method for preparing the reagent card for quantitatively detecting tumor necrosis factor alpha according to claim 4, wherein the method comprises the following steps: and after the fourth step is finished, filling the reagent card for quantitatively detecting the tumor necrosis factor alpha and the drying agent into an aluminum foil bag, sealing and packaging.
6. The method for preparing the reagent card for quantitatively detecting tumor necrosis factor alpha according to claim 4 or 5, wherein the reagent card comprises: the first step is carried out according to the following step sequence,
firstly), adding a marking buffer solution into a fluorescent material, and diluting the fluorescent material to 0.2-0.3% to obtain a solution A;
wherein the amount of fluorescent material = batch volume × target fluorescent material concentration 0.25% ÷ original fluorescent material concentration 1%, the amount of added labeling buffer = batch volume-fluorescent material volume;
secondly), centrifuging the solution A for 10-20 minutes under the conditions of 12000-13000rpm, discarding the supernatant, redissolving the precipitate by using a marking buffer solution, performing ultrasonic treatment, centrifuging for 10-20 minutes under the conditions of 12000-13000rpm, discarding the supernatant, adding the marking buffer solution, and performing ultrasonic treatment to obtain a solution B;
thirdly) adding the EDC solution with the concentration of 0.01-0.03mL/mL and the NHS solution with the concentration of 0.08-0.2mL/mL into the solution B, and uniformly mixing for 0.5-1.5 hours to obtain a solution C;
wherein, the dosage of EDC solution = batch volume (0.01-0.03) mL/mL, and the dosage of NHS solution = batch volume (0.08-0.2) mL/mL;
centrifuging the solution C for 10-20 minutes under the conditions of 12000-13000rpm, discarding the supernatant, redissolving the precipitate by using a marking buffer solution, and performing ultrasonic treatment to obtain a solution D;
adding the antibody into the solution D, and stirring for 2-4 hours to obtain a solution E;
wherein the antibody dosage = batch volume × target antibody concentration 0.1-0.3mg/mL ÷ antibody concentration
Centrifuging the solution E for 10-20 minutes under the conditions of 12000-13000rpm, removing the supernatant, adding the TBS solution with batch volume into the precipitate, ultrasonically mixing the solution uniformly, and stirring the solution for 3-5 hours to obtain a solution F;
centrifuging the solution F for 10-20 minutes under the conditions of 12000-13000rpm, re-dissolving the precipitated immune material into a batch volume by using TBS, and performing ultrasonic treatment at 160-220W to obtain an immunofluorescence material diluted solution;
fourthly) spraying the immunofluorescence material diluted solution to a release pad according to the parameter of 2.0-3.0 mu L/cm, and then drying for 4-24 hours at the temperature of 40-45 ℃ to obtain the immunofluorescence material release pad;
batch volume refers to the volume of the immunofluorescent material dilution solution.
7. The method for preparing the reagent card for quantitatively detecting tumor necrosis factor alpha according to claim 6, wherein the reagent card comprises: the second step is carried out according to the following step sequence,
① quality control line solution preparation
Measuring a goat anti-mouse IgG solution, diluting the goat anti-mouse IgG solution with a CT-S buffer solution until the final concentration is 0.8-1.5mg/mL, and storing the diluted goat anti-mouse IgG solution at the temperature of 2-8 ℃ for later use;
② TNF alpha detection line solution preparation
Measuring an anti-TNF alpha monoclonal antibody-2, diluting the anti-TNF alpha monoclonal antibody-2 by using a CT-S buffer solution until the final concentration is 0.8-1.5mg/mL, and storing the anti-TNF alpha monoclonal antibody-2 at the temperature of 2-8 ℃ for later use;
③ spraying the prepared quality control line solution onto the nitrocellulose membrane according to the parameter of 2.0-3.0 μ L/cm to prepare a quality control line, spraying the prepared TNF alpha detection line solution onto the nitrocellulose membrane to prepare a TNF alpha detection line, and drying the nitrocellulose membrane at 40-45 deg.C for 4-24 hr to obtain the immune nitrocellulose membrane.
8. The method for preparing the reagent card for quantitatively detecting tumor necrosis factor alpha according to claim 7, wherein the reagent card comprises: the third step is carried out according to the following step sequence,
i, sticking the immune nitrocellulose membrane at the middle position of the gasket;
II, attaching the water absorbing paper to the water absorbing paper end of the lining, covering the upper end of the attached immune nitrocellulose membrane downwards, covering the immune nitrocellulose membrane by 1.5-2 mm, and pressing;
III, attaching the immunofluorescence material release pad to the lower end of the immunonitrocellulose membrane, covering the immunonitrocellulose membrane by 1.5-2 mm, and pressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911032652.2A CN110687301A (en) | 2019-10-28 | 2019-10-28 | Reagent card for quantitatively detecting tumor necrosis factor alpha and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911032652.2A CN110687301A (en) | 2019-10-28 | 2019-10-28 | Reagent card for quantitatively detecting tumor necrosis factor alpha and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110687301A true CN110687301A (en) | 2020-01-14 |
Family
ID=69114395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911032652.2A Pending CN110687301A (en) | 2019-10-28 | 2019-10-28 | Reagent card for quantitatively detecting tumor necrosis factor alpha and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110687301A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115856290A (en) * | 2022-12-15 | 2023-03-28 | 无锡市第二人民医院 | Fluorescent immune quantitative test strip for detecting calcium-binding protein A9, and detection method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
| CN102539778A (en) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha |
| CN105092861A (en) * | 2015-09-14 | 2015-11-25 | 广州市微米生物科技有限公司 | Immunofluorescence chromatography test paper for CRP (C-reaction protein)/SAA (Serum amyloid A protein) quantitative combined detection and preparation method of immunofluorescence chromatography test paper |
| CN207717778U (en) * | 2016-12-30 | 2018-08-10 | 苏州和锐生物科技有限公司 | TNF-α time-resolved fluoroimmunoassay chromatographs immue quantitative detection reagent box |
-
2019
- 2019-10-28 CN CN201911032652.2A patent/CN110687301A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
| US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| CN102539778A (en) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha |
| CN105092861A (en) * | 2015-09-14 | 2015-11-25 | 广州市微米生物科技有限公司 | Immunofluorescence chromatography test paper for CRP (C-reaction protein)/SAA (Serum amyloid A protein) quantitative combined detection and preparation method of immunofluorescence chromatography test paper |
| CN207717778U (en) * | 2016-12-30 | 2018-08-10 | 苏州和锐生物科技有限公司 | TNF-α time-resolved fluoroimmunoassay chromatographs immue quantitative detection reagent box |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115856290A (en) * | 2022-12-15 | 2023-03-28 | 无锡市第二人民医院 | Fluorescent immune quantitative test strip for detecting calcium-binding protein A9, and detection method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103116023B (en) | ECL (electrochemiluminescence) immunosensor for detecting tumor markers and preparation method and applications thereof | |
| CN101762706B (en) | Method of detecting residue of small-molecule substance harmful to human body and a special kit | |
| CN110221084B (en) | Nano-selenium kit for rapidly detecting HE4 and CA125 | |
| CN111610335B (en) | Time-resolved fluorescence immunochromatography test strip, kit containing same and application thereof | |
| EP0446304A1 (en) | Immunometric assay for tumor necrosis factor-alpha | |
| CN110470832B (en) | Hollow bimetallic test strip for simultaneously detecting IL-6, IL-4 and TNF-alpha and preparation method thereof | |
| CN111239421A (en) | Latex-enhanced immunoturbidimetry kit for quantitatively detecting adiponectin ADPN and preparation and application methods thereof | |
| CN108445230B (en) | Procalcitonin chemiluminescence detection reagent based on nano antibody and detection method | |
| CN207717778U (en) | TNF-α time-resolved fluoroimmunoassay chromatographs immue quantitative detection reagent box | |
| CN106918708A (en) | A kind of competition law turbid kit of latex enhancing immune transmittance for detecting insulin | |
| CN106226523A (en) | Detection method, reagent and the detection kit of a kind of immunological marker thing | |
| CN202916286U (en) | Latex enhanced turbidimetric immunoassay kit for quantitatively detecting procalcitonin (PCT) | |
| CN108845143A (en) | A kind of PCT-CRP dual card and preparation method thereof | |
| CN109188000A (en) | A kind of test strips and preparation method thereof of portable inspectiont human parathyroid hormone | |
| CN108795880A (en) | Generate people's thymidine kinase 1（TK1）The mouse hybridoma cell strain of monoclonal antibody specific and its application | |
| CN110687301A (en) | Reagent card for quantitatively detecting tumor necrosis factor alpha and preparation method thereof | |
| CN201087838Y (en) | Myocardium calcium protein I color particle diagnosis test paper | |
| CN109917138A (en) | A kind of myoglobins time-resolved fluoroimmunoassay measurement in chromatography kit | |
| ATE143673T1 (en) | TESTING METHOD OF GLYCOSYLATED PROTEINS USING AN ANTIBODIES DIRECTED AGAINST REDUCED GLYCOSYLATED N-TERMINAL AMINO ACIDS | |
| Nomura et al. | Serum and tissue vascular endothelial growth factor levels in hydatidiform mole | |
| CN108267594A (en) | A kind of ST2 detection kits, method of preparation and use based on bimolecular fluorescence complementary technology | |
| KR940008091B1 (en) | Method for the immunological determination of ligands | |
| CN113912677B (en) | Hepatitis C virus detection related peptide and visible time-resolved fluorescent microsphere test strip thereof | |
| CN110514831A (en) | A kind of colloidal gold fast detecting test paper strip of Brucella bp 26 protein epitope fusion protein and its application | |
| CN210665765U (en) | NTx detection test paper and NTx detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200114 |
|
| RJ01 | Rejection of invention patent application after publication |